Open Orphan rockets! Why I think it will double your money

Open Orphan stock is soaring on its Covid-19 test. And it should outlast the hype to continue growing, predicts Tom Rodgers

The content of this article was relevant at the time of publishing. Circumstances change continuously and caution should therefore be exercised when relying upon any content contained within this article.

When investing, your capital is at risk. The value of your investments can go down as well as up and you may get back less than you put in.

Read More

The content of this article is provided for information purposes only and is not intended to be, nor does it constitute, any form of personal advice. Investments in a currency other than sterling are exposed to currency exchange risk. Currency exchange rates are constantly changing, which may affect the value of the investment in sterling terms. You could lose money in sterling even if the stock price rises in the currency of origin. Stocks listed on overseas exchanges may be subject to additional dealing and exchange rate charges, and may have other tax implications, and may not provide the same, or any, regulatory protection as in the UK.

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More.

Anglo-Irish pharma firm Open Orphan (LSE:ORPH) is my choice for the next big thing in UK biopharma, and its Covid-19 test is just one string to its bow.

The AIM-listed company has seen a dramatic rise. Since January the share price has grown from 5.5p to 14p. In that time, its market cap has surged from £30m to £78m. Most of that is down to froth, rumour and hype from its potential Covid-19 antibody test.

Open Orphan has just announced a deal with NASDAQ-listed Swiss firm Quotient to produce Covid-19 antibody tests at a rate of 3,000 per day. Home testing kits can sell from anywhere between £70 to £150.

With the UK government’s commitment to ramp up testing to help reopen the shuttered economy, this could be a major revenue generator for such a small company.

Caveat

I do own shares in Open Orphan, which puts me at risk of endowment bias. This is where investors are more positive about the future prospects of stocks they own, than those they do not. So of course, like all biopharma stocks, it could fall flat. Drug trials could fail or not be commercially viable. And there is certainly much greater risk on AIM than in the FTSE 100 or FTSE 250.

But I think the share price can still double because the market is only just starting to wake up to Open Orphan. And secondly, it has strong revenues in the pipeline that have nothing to do with Covid-19.

Fool’s Gold

Tiny pharmaceutical companies have become the new gold rush for UK investors. Most are unprofitable. Release some news related to Covid-19 tests or treatments? Your share price soars.

It happened with Novacyt. I covered this Anglo-French stock in April when it shot up 2,750%. Then there’s Synairgen, Omega Diagnostics, Avacta, 4D Pharma, the list goes on.

Most of these are trading on ridiculous multiples and crazy valuations, driven by investor Fear Of Missing Out. When short-term momentum fades, their share prices will too, I feel. But I don’t think that’s the case with Open Orphan.

Where next

I set a lot of store by companies with strong economic moats, or competitive advantages. This is Warren Buffett’s favourite metric for good reason. After all, if just anyone can swoop in and manufacture or sell your product at a lower cost or higher margin, you may not have a long-term business that will last.

I believe no company of its type can match Open Orphan’s portfolio of viral challenge study models. They cover flu — including a candidate for a universal flu vaccine — asthma and COPD. It has announced £10m in revenue this year alone from human challenge studies unrelated to Covid-19. That includes two contracts, worth £3.2m and £3.5m each for human challenge studies that for treatments for Respiratory Syncytial Virus (RSV), an extremely common virus that causes lung infections in young babies.

It has one other unimpeachable advantage its competitors do not: its studies run at its own quarantine unit in Queen Mary’s Hospital, London. This 24-bed clinic is Europe’s only commercial venue with a quarantine unit and virology laboratory on-site. This makes its drugs testing process ultra-efficient.

So when the hype around Covid-19 stocks begins to subside, when tens of millions of tests have been distributed and taken, I believe Open Orphan will continue to thrive.

Should you invest, the value of your investment may rise or fall and your capital is at risk. Before investing, your individual circumstances should be assessed. Consider taking independent financial advice.

Tom Rodgers owns shares in Open Orphan. The Motley Fool UK has no position in any of the shares mentioned. Views expressed on the companies mentioned in this article are those of the writer and therefore may differ from the official recommendations we make in our subscription services such as Share Advisor, Hidden Winners and Pro. Here at The Motley Fool we believe that considering a diverse range of insights makes us better investors.

More on Investing Articles

Mature couple at the beach
Investing Articles

6 stocks that Fools have been buying!

Our Foolish freelancers are putting their money where their mouths are and buying these stocks in recent weeks.

Read more »

Black woman using loudspeaker to be heard
Investing Articles

I was right about the Barclays share price! Here’s what I think happens next

Jon Smith explains why he still feels the Barclays share price is undervalued and flags up why updates on its…

Read more »

Investing Articles

Where I’d start investing £8,000 in April 2024

Writer Ben McPoland highlights two areas of the stock market that he would target if he were to start investing…

Read more »

View of Tower Bridge in Autumn
Investing Articles

Ahead of the ISA deadline, here are 3 FTSE 100 stocks I’d consider

Jon Smith notes down some FTSE 100 stocks in sectors ranging from property to retail that he thinks could offer…

Read more »

Young female business analyst looking at a graph chart while working from home
Investing Articles

Why I think Rolls-Royce shares will pay a dividend in 2024

Stephen Wright thinks Rolls-Royce shares are about to pay a dividend again. But he isn’t convinced this is something investors…

Read more »

Investing Articles

1 of the best UK shares to consider buying in April

Higher gold prices and a falling share price have put this FTSE 250 stock on Stephen Wright's list of UK…

Read more »

Person holding magnifying glass over important document, reading the small print
Investing Articles

The market is wrong about this FTSE 250 stock. I’m buying it in April

Stephen Wright thinks investors should look past a 49% decline in earnings per share and consider investing in a FTSE…

Read more »

Black father and two young daughters dancing at home
Investing Articles

1 FTSE 250 stock I own, and 1 I’d love to buy

Our writer explains why she’s eyeing up this FTSE 250 growth phenomenon, and may buy more shares in this property…

Read more »